BSE Code: | NSE Code: | ISIN: | Sector:
Research Report Detail
|Report Date||Call||Price@Call||Target Price
|Current Status||Time Horizon|
|Target Hit|| Long (1Y)
Religare retains hold on Divis Laboratories
Divis management expects a 5 per cent impact on the company's overall revenues due to the ban for Unit-II, which accounts for 22-23 per cent of its US direct and indirect sales, as most products from the unit were exempted.